Biopsy-confirmed fenofibrate-induced severe jaundice: A case report

1Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.
Get full text

Abstract

BACKGROUND Drug-induced liver injury (DILI) is the leading cause of acute liver failure in the United States. DILI is mainly caused by painkillers and fever reducers, and it is often characterized by the type of hepatic injury (hepatocellular or cholestatic). This report presents a case of fenofibrate-induced severe jaundice in a 65-year-old Korean male with no prior history of liver disease. We offer a strategy for patients who present signs of severe liver injury with jaundice and high elevations in serum transaminases. CASE SUMMARY A 65-year-old male visited the gastroenterology outpatient clinic of a tertiary hospital due to increased levels of liver enzyme and total bilirubin which were incidentally detected through a preoperative screening test. Abdominal ultrasound and computed tomography showed no biliary obstruction or nonspecific findings in the liver. Liver biopsy was performed and the patient was finally diagnosed with acute cholestatic hepatitis. Following the biopsy, steroid therapy was initiated and after 3 wk of treatment, the total bilirubin level was reduced to 7.22 mg/dL. CONCLUSION In patients with hyperlipidemia, treatment including fenofibric acid induces rare complications such as severe jaundice and acute cholestatic hepatitis, warranting clinical attention.

Cite

CITATION STYLE

APA

Lee, H. Y., Lee, A. R., Yoo, J. J., Chin, S., Kim, S. G., & Kim, Y. S. (2021). Biopsy-confirmed fenofibrate-induced severe jaundice: A case report. World Journal of Clinical Cases, 9(30), 9295–9301. https://doi.org/10.12998/wjcc.v9.i30.9295

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free